跳至主要内容
临床试验/NCT05346185
NCT05346185进行中(未招募)不适用

Association of Preoperative Sarcopenia on Postoperative Outcomes After Lung Cancer Surgery: Prospective Observational Study

Seoul National University Hospital1 个研究点 分布在 1 个国家目标入组 400 人开始时间: 2021年4月13日最近更新:
适应症

试验速览

阶段
不适用
状态
进行中(未招募)
入组人数
400
试验地点
1
主要终点
overall survival

研究概览

简要总结

The presence of sarcopenia before lung resection surgery might be an important factor of short-term and long-term prognosis in lung cancer patients. Through this study, investigators plan to demonstrate evidence whether sarcopenia is a useful clinical biomarker for risk stratification in elderly patients undergoing lung cancer surgery.

详细描述

Sarcopenia is a syndrome characterized by a decrease in the amount and function of skeletal muscle, and is known to have a prevalence of about 6-10% in 65 years of age or older and about 20-25% in 70 years of age or older. Recently, many studies have been conducted on the clinical importance of sarcopenia, and it has been reported that sarcopenia is significantly associated with a decline in quality of life and physical activity in the elderly population, as well as harmful clinical outcomes in postoperative patients and poor long-term outcomes in various solid cancer patients. Due to the promising result of lung cancer screening trial, lung cancer has been included in national cancer screening in South Korea since last year. As a result, more people are being diagnosed with lung cancer early. Furthermore, the number of patients having surgical resection for lung cancer is steadily growing, and as life expectancy rises, even older patients are increasingly considering surgical treatment. It's critical to appropriately assess risk in older individuals before and after surgery, and sarcopenia is considered a significant fartor for major surgery. According to studies on the association between sarcopenia and the postoperative clinical outcome of lung cancer surgery, sarcopenia evaluated by computed tomography has demonstrated to be associated with a poor surgical outcome and long-term prognosis. However, according to two recognized guidelines for sarcopenia (European Working Group on Sarcopenia in Elder People, and Asian Working Group for Sarcopenia), sarcopenia is supposed to comprehensively evaluate muscle mass, muscle strength, and physical activity. Regarding muscle mass, it is recommended to measure through dual energy-ray absoptiometery or bioelectrial impedance analysis. However, so far, there are no studies that have conducted an accurate evaluation of sarcopenia in elderly lung cancer patients and analyzed the relationship between them and the clinical outcome after lung cancer surgery.

研究设计

研究类型
Observational
观察模型
Cohort
时间视角
Prospective

入排标准

年龄范围
70 Years 至 —(Older Adult)
性别
All
接受健康志愿者

入选标准

  • Patients planning to perform curative surgery for confirmed lung cancer and pulmonary nodules suspected for lung cancer
  • Patients or legal representatives who could understand and write written consent prior to the initiation of the clinical trial and are able to comply with the requirements for the clinical trial

排除标准

  • Patients with treatment history for lung cancer or other solid cancer within 5 years (except patients with adenocarcinoma in situ for lung cancer)
  • Patients who need simultaneous surgery with lung caner surgery for other accompanying diseases
  • Patients who are not eligible to participate in the study judged by the researcher

结局指标

主要结局

overall survival

时间窗: 5 years after the day of lung cancer surgery

survival status during the follow-up after the lung cancer surgery

次要结局

  • recurrence free survival(up to 5 years after the day of lung cancer surgery)
  • quality of life questionnaire(before the surgery, at postoperative 1 year, and at postoperative 5 year)
  • non-cancer related mortality(up to 5 years after the day of lung cancer surgery)
  • postoperative change of pulmonary function(at postoperative 1 year, 5 year)
  • postoperative complication rate(from the day of lung cancer surgery to the discharge after lung cancer surgery (up to 6 months))
  • operative mortality(from the day of lung cancer surgery to the discharge after lung cancer surgery (up to 6 months))
  • length of stays(from the day of lung cancer surgery to the discharge after lung cancer surgery (up to 6 months))
  • cognitive function questionnaire(before the surgery, and at postoperative 5 year)
  • geriatric depression scale questionnaire(before the surgery, at postoperative 1 year, and at postoperative 5 year)

研究者

申办方类型
Other
责任方
Principal Investigator
主要研究者

In Kyu Park

Professor

Seoul National University Hospital

研究点 (1)

Loading locations...

相似试验

Lung Cancer Surgery in Sarcopenia Patients With Old... | 临床试验